SEC Tracker
Get the app

Sanara MedTech SMTI

MIMEDX Announces Q3 2026 Results

Merger communication

Form
425
Filed
Importance
Routine
  1. Net sales of $62 million for Q3 2026
  2. Surgical product sales up 9% year-over-year
  3. Wound sales down 71% year-over-year
  4. Adjusted EBITDA turned positive in Q3 2026

Written from the 425 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Sanara MedTech files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3842 and related industry codes: the same peer list as the financial tables.

  1. Anika Therapeutics ANIK public float $147M, Jun 30, 2025
  2. Stereotaxis STXS public float $150M, Jun 30, 2025
  3. Profound Medical PROF public float $152M, Jun 30, 2025
  4. Sight Sciences SGHT public float $154M, Jun 30, 2025
  5. AVITA Medical RCEL public float $139M, Jun 30, 2025